{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:20:23Z","timestamp":1790886023351,"version":"4.1.0"},"reference-count":28,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["iABC [Grant 115721]"],"award-info":[{"award-number":["iABC [Grant 115721]"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Culture-independent molecular techniques could potentially be used to measure microbiological efficacy in response to antibiotic treatment and improve understanding of the role of the airway microbiota in determining response in patients with chronic respiratory disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using molecular methods, we analysed changes in the sputum microbiota in samples from 107 participants with bronchiectasis recruited to the iBEST-1 study, and defined community endotypes based on response to tobramycin inhalation powder (TIP) treatment. The relationship between microbiota metrics in these endotypes and clinical and inflammatory biomarkers were also determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was a significant reduction in\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      density, measured by quantitative polymerase chain reaction (qPCR), between Days 1 and 29 for participants in the TIP treatment (n=63; p&lt;0.0001) but not placebo (n=20; p&gt;0.05) group. Based on decrease in\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      density (\n                      <jats:italic>oprL<\/jats:italic>\n                      copies\u00b7mL\n                      <jats:sup>\u22121<\/jats:sup>\n                      ) over 28\u2005days, two clusters of participants receiving TIP were observed and stratified as either responders (\u22652Log\n                      <jats:sub>10<\/jats:sub>\n                      ; n=26) or non-responders (&lt;2Log\n                      <jats:sub>10<\/jats:sub>\n                      ; n=37). In responders, a shift to a microbial community structure less dominated (p=0.018) by a pathogen was apparent and associated with a greater improvement in inflammatory and fewer participant exacerbations in the following 6\u2005months (27%\n                      <jats:italic>versus<\/jats:italic>\n                      49%; p=0.117) when compared to non-responders. Lung function was higher at Day 1 in responders (\n                      <jats:sub>median<\/jats:sub>\n                      =64.6% predicted) than non-responders (\u03bc\u0303\n                      <jats:sub>median<\/jats:sub>\n                      =50.3% predicted) and independently predicted response to treatment with TIP (p=0.013).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>qPCR may be a useful, culture-independent microbiological efficacy end-point in clinical trials. Using qPCR, participants with bronchiectasis were stratified into endotpyes which predicted response to antimicrobial treatment, potentially allowing for a more personalised approach to therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00389-2025","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T20:01:27Z","timestamp":1752782487000},"page":"00389-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular endotyping in people with bronchiectasis based on response to antibiotic treatment: iBEST study"],"prefix":"10.1183","volume":"11","author":[{"given":"Gisli G.","family":"Einarsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Sherrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Alkhatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre F.","family":"Gilpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhild","family":"Angyalosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Loebinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5628-6667","authenticated-orcid":false,"given":"Harm A.W.M.","family":"Tiddens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-4968","authenticated-orcid":false,"given":"Felix C.","family":"Ringshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Tunney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2025122901500878000_11.6.00389-2025.1","doi-asserted-by":"crossref","first-page":"106285","DOI":"10.1016\/j.rmed.2020.106285","article-title":"Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study","volume":"177","author":"Choate","year":"2021","journal-title":"Respir Med"},{"key":"2025122901500878000_11.6.00389-2025.2","doi-asserted-by":"crossref","first-page":"104174","DOI":"10.1016\/j.lpm.2023.104174","article-title":"Bronchiectasis","volume":"52","author":"Barbosa","year":"2023","journal-title":"Presse Med"},{"key":"2025122901500878000_11.6.00389-2025.3","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00021-2023"},{"key":"2025122901500878000_11.6.00389-2025.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0487OC"},{"key":"2025122901500878000_11.6.00389-2025.5","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"2025122901500878000_11.6.00389-2025.6","unstructured":"Committee for Medicinal Products for Human Use (CHMP) . Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis, 2009. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-development-medicinal-products-treatment-cystic-fibrosis-first-version_en.pdf"},{"key":"2025122901500878000_11.6.00389-2025.7","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur Respir J"},{"key":"2025122901500878000_11.6.00389-2025.8","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1164\/rccm.202303-0499OC","article-title":"Inflammatory molecular endotypes in bronchiectasis: a European multicenter cohort study","volume":"208","author":"Choi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025122901500878000_11.6.00389-2025.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202310-1729OC"},{"key":"2025122901500878000_11.6.00389-2025.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1059OC"},{"key":"2025122901500878000_11.6.00389-2025.11","doi-asserted-by":"crossref","first-page":"101834","DOI":"10.1016\/j.pupt.2019.101834","article-title":"Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: design of a dose-finding study (iBEST-1)","volume":"58","author":"Loebinger","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"2025122901500878000_11.6.00389-2025.12","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-148-1-257"},{"key":"2025122901500878000_11.6.00389-2025.13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-9-244"},{"key":"2025122901500878000_11.6.00389-2025.14","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3612-9"},{"key":"2025122901500878000_11.6.00389-2025.15","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2634"},{"key":"2025122901500878000_11.6.00389-2025.16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1164\/rccm.201809-1651OC","article-title":"Airway bacterial load and inhaled antibiotic response in bronchiectasis","volume":"200","author":"Sibila","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025122901500878000_11.6.00389-2025.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2020"},{"key":"2025122901500878000_11.6.00389-2025.18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025122901500878000_11.6.00389-2025.19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025122901500878000_11.6.00389-2025.20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025122901500878000_11.6.00389-2025.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49150-y"},{"key":"2025122901500878000_11.6.00389-2025.22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-2600(20)30557-9","article-title":"The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study","volume":"9","author":"Dicker","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025122901500878000_11.6.00389-2025.23","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.2.9910086"},{"key":"2025122901500878000_11.6.00389-2025.24","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E099"},{"key":"2025122901500878000_11.6.00389-2025.25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/crj.12278","article-title":"Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis","volume":"10","author":"Yang","year":"2016","journal-title":"Clin Respir J"},{"key":"2025122901500878000_11.6.00389-2025.26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/resp.13653","article-title":"Composition of airway bacterial community correlates with chest HRCT in adults with bronchiectasis","volume":"25","author":"O'Neill","year":"2020","journal-title":"Respirology"},{"key":"2025122901500878000_11.6.00389-2025.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2010.10.003"},{"key":"2025122901500878000_11.6.00389-2025.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400104"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00389-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:50:20Z","timestamp":1767001820000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00389-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12,29]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1183\/23120541.00389-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00389-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}